| ||Audit Committee||Compensation Committee|
|Philippe Amouyal |
Philippe Amouyal has been a director since 2007. Philippe is a Managing Director of Invus. He joined Invus in 1999. Philippe is a director of
Weight Watchers and Lexicon Pharmaceuticals and also serves on the boards of a number of private Artal or Invus portfolio companies. Prior to joining
Invus, Philippe spent 15 years at the Boston Consulting Group in Paris and Boston, where he was a Vice President and Director and coordinated the global
electronics and software practice from 1991 on. He h...
|Evren Bilimer |
Evren Bilimer has been a director since 2012. Evren is a Managing Director of Invus. He joined Invus in 2002. Evren has served on the boards of a
number of private Invus portfolio companies. Prior to joining Invus, Evren was a management consultant with McKinsey & Company in New York, where he
worked with clients in a wide range of industries including the consumer sector and financial services. Evren graduated summa cum laude from Yale
University double majoring in electrical engineering and...
|Michael A. Eck
|Michael A. Eck|
Michael (“Mike”) A. Eck has been a director since 2015. Mike was the Global Head of the Consumer and Retail Investment Banking Group at
Morgan Stanley from 2008 to 2014 until his retirement. Prior to that, Mike worked at Citigroup from 1993 to 2008, where he was most recently the Global
Head of the Consumer and Retail Investment Banking Group, and at Credit Suisse First Boston from 1987 to 1993. Mike is a senior advisory board member
of Shopkick, a board member of USA Ultimate, and the co-fou...
|Frances Frei |
Frances Frei has been a director since 2014. Frances is the UPS Foundation Professor of Service Management at Harvard Business School since
July 2009, and has served as the Senior Associate Dean at Harvard Business School since July 2012. In addition, she was Chair of the MBA Required
Curriculum at Harvard Business School and Course Head of the school’s innovative FIELD (Field Immersion Experience for Leadership Development)
Method Course, which is Harvard Business School’s companion to the c...
|Amy Schulman |
|Amy Schulman |
Amy Schulman has been a director since 2014. Amy is the Chief Executive Officer of Arsia Therapeutics, a Venture Partner in Polaris Partners, and
a Senior Lecturer at Harvard Business School. Amy is a director of Alnylam Pharmaceuticals and Bind Therapeutics. Amy was previously the Executive Vice
President and General Counsel of Pfizer from 2008 to 2013 and served as the Business Unit Lead for Pfizer’s Consumer Healthcare business from 2012 to
2013. Prior to Pfizer, Amy was a Partner at DLA P...